Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compositions comprising Anti-cd38 antibodies and carfilzomib

a technology which is applied in the field of anti-cd38 antibodies and carfilzomib, and cancer treatments, and can solve the problems of patients succumbing to their illness and unable to resis

Inactive Publication Date: 2016-01-28
RGT UNIV OF CALIFORNIA +1
View PDF3 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent is about the need for better treatments for multiple myeloma and blood cancers that can help people live longer and have better outcomes.

Problems solved by technology

While these agents have improved survival in multiple myeloma, invariably resistance becomes problematic and patients succumb from their illness.
Unfortunately, like various drugs and chemotherapies, not all antibodies are the same and not all antibodies against the same antigen exhibit the same activities.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions comprising Anti-cd38 antibodies and carfilzomib
  • Compositions comprising Anti-cd38 antibodies and carfilzomib
  • Compositions comprising Anti-cd38 antibodies and carfilzomib

Examples

Experimental program
Comparison scheme
Effect test

example 1

Effect of the Administration of Both Anti-CD38 Antibody and Carfilzomib in a Mice Model of MM

[0074]These studies under this Example were done under approval of the UCSF IACUC.

[0075]The subcutaneous multiple myeloma (MM) xenograft mouse models were established using NCI-H929 or RPMI-8226 cell lines. Specifically, 5-6 week old female Balb / c Scid mice were obtained from Jackson Lab. Mice were housed for 7-10 days prior to implantation. Mice were housed in a dedicated room in the UCSF Mt Zion Animal Barrier Facility. NCI-H929 and RPMI-8226 cells were obtained from the German Collection of Microorganisms and Cell Cultures, DSMZ, (Deutsche Sammlung von Mikroorganismen and Zellkulturen), and grown in sterile suspension culture in T225 flasks as follows: NCI-H929: RPMI1640+20% FBS+4 mM L-glutamine+1 mM sodium pyruvate+50 μM mercaptoethanol. RPMI-8226: RPMI1640+10% FBS+4 mM L-glutamine.

[0076]At the time of implantation, mice were shaved on the right flank and shoulder region and anesthetized...

example 2

Effect of the Administration of Both Anti-CD38 Antibody and Carfilzomib in Humans

[0085]A clinical study for evaluating the effects of a treatment with hu38SB19 combined with carfilzomib in patients with relapsed or refractory multiple myeloma may be performed as described below.

[0086]The goals of the study may include:[0087]To determine the efficacy and the maximum tolerated dose;[0088]To evaluate the safety, including immunogenicity, of hu38SB19 in combination with carfilzomib in relapse or refractory multiple myeloma. The severity, frequency and incidence of all toxicities is assessed;[0089]To evaluate the pharmacokinetics (PK) of hu38SB19 when administered in combination with carfilzomib and the PK of carfilzomib in combination with hu38SB19, and optionally dexamethasone.[0090]To assess the relationship between clinical (adverse event and / or tumor response) effects and pharmacologic parameters (PK / pharmacodynamics), and / or biologic (correlative laboratory) results;[0091]Estimate ...

example 3

Efficacy of Anti-CD38 Antibody in In Vivo Tumor Models of Multiple Myeloma as a Single-Agent or in Combination with and Carfilzomib

A. Materials and Methods

[0102]CD38 Density: CD38 density was determined using anti-CD38-PE Quantibrite (BD Biosciences; Cat.342371) per the manufacturer's recommended protocols.

[0103]Reagents & Compounds: hu38SB19 was provided by Sanofi Oncology in solution at 5 mg / ml and stored at 4° C. hu38SB19 was diluted into sterile saline in preparation for dosing and used within 10 days of dilution. hu38SB19 was administered twice weekly×2 wk IV. Carfilzomib (PR-171) was obtained from Chemie Tek (CT-CARF 98). Carfilzomib was formulated in an aqueous solution of 10% (w / v) sulfobutylether-h-cyclodextrin (Cydex) and 10 mmol / L sodium citrate (pH 3.5), 2 mg / ml stock prepared and frozen at −80° C., diluted daily with vehicle before injection. Carfilzomib was administered weekly qd×2×3 wk (iv).

[0104]Test Animals: 5-6 week old female Balb / c Scid mice were obtained from Ja...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
pHaaaaaaaaaa
volumeaaaaaaaaaa
volumeaaaaaaaaaa
Login to View More

Abstract

Disclosed herein are compositions and kits which comprise anti-CD38 antibodies and carfilzomib compounds. Also disclosed are methods for treating cancers, such as multiple myeloma, in subjects with the compositions and kits.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims the benefit of U.S. Application No. 61 / 778,540, filed 13 Mar. 2013, and U.S. Application No. 61 / 808,381, filed 4 Apr. 2013, all of which are herein incorporated by reference in their entirety.REFERENCE TO A SEQUENCE LISTING SUBMITTED VIA EFS-WEB[0002]The content of the ASCII text file of the sequence listing named “20140313—034543—002WO1_seq” which is 56.7 kb in size was created on 13 Mar. 2014 and electronically submitted via EFS-Web herewith the application is incorporated herein by reference in its entirety.BACKGROUND OF THE INVENTION[0003]1. Field of the Invention[0004]The field of the present invention relates to anti-CD38 antibodies, carfilzomib, and cancer treatments.[0005]2. Description of the Related Art[0006]Multiple myeloma (MM) is a B cell malignancy. In MM, abnormal plasma cells accumulate in the bone marrow where they interfere with the production of normal cells. Current therapy of MM includes admini...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395A61K9/00A61K31/573A61K38/07A61K38/08
CPCA61K39/39558A61K38/07A61K31/573A61K2039/54A61K9/0053A61K2039/505A61K9/0019C07K16/2896C07K16/3061C07K2317/24C07K2317/73C07K2317/732C07K2317/734A61K38/08A61P35/00A61P35/02A61P43/00A61K2300/00A61K39/39533C07K2317/56A61K2039/545A61K31/5377A61K31/336A61K39/395C07K16/28
Inventor TOMKINSON, BLAKEAFTAB, BLAKE T.HANN, BYRON C.MARTIN, III, THOMAS G.
Owner RGT UNIV OF CALIFORNIA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com